(Bloomberg) Novo Nordisk A/S diabetes drug Ozempic showed surprisingly early effectiveness in a kidney-failure study, sending shares of the world’s biggest dialysis providers tumbling.Most Read from BloombergIsrael Latest: Sirens Sound in North, Biden Speaks to NetanyahuIsrael Latest: Israeli Death Toll in Hamas Attack Reaches 1,200Israel Forms Emergency Government for War Against HamasHamas Got Around Israel’s Surveillance Prowess by Going DarkIMF Caught Off Guard as China Strikes Sri Lanka
NAV CHANGECHANGE IN EPS2023 : € 2.12 vs 2.12 2024 : € 2.23 vs 2.26 -1.51%Novo Nordisk’s semaglutide has shown good efficacy in a phase III trial assessing injectable semaglutide for the.
(Bloomberg) The disruptive impact on stock markets of Novo Nordisk A/S’s diabetes drugs is getting ever wider. Most Read from BloombergIsrael Latest: Sirens Sound in North, Israel Forms War CabinetIsrael Latest: Israeli Death Toll in Hamas Attack Reaches 1,200Hamas Got Around Israel’s Surveillance Prowess by Going DarkIsrael Forms Emergency Government for War Against HamasIMF Caught Off Guard as China Strikes Sri Lanka Debt DealThe Danish company, now Europe’s largest by market value, said la